MiniMed Expands Agreement with Abbott
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
MiniMed (MMED) announced an expanded agreement with Abbott (ABT) to collaborate on commercializing dual glucose-ketone sensors designed to integrate exclusively with MiniMed smart dosing systems. These new dual monitoring sensors are designed to enable early, real-time detection of rising ketones to help prevent diabetic ketoacidosis. The agreement builds on the companies' existing partnership for the Instinct sensor, made by Abbott, and will offer MiniMed users expanded choice across its automated insulin delivery and Smart MDI systems. The sensors will be the same size as the Instinct sensor.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MMED?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MMED
Wall Street analysts forecast MMED stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 14.260
Low
Averages
High
Current: 14.260
Low
Averages
High
About MMED
MiniMed Group, Inc. is a medical technology company, which develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Its fully integrated system addresses pain points for people with diabetes (PWD): health outcomes and complexity of diabetes management. The MiniMed 780G is its flagship AID system. The MiniMed 780G system uses its SmartGuard dosing algorithm technology, which automatically delivers basal insulin and auto-correction doses every five minutes based on sensor glucose readings. The MiniMed 780G consists of the MiniMed 780G insulin pump, the Simplera Sync CGM sensor, and the instinct sensor. Its platform of clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and a Smart Multiple Daily Injection (MDI) System. Its pipeline products are the MiniMed Flex, screenless insulin pump, next-generation Vivera dosing algorithm, and MiniMed Fit patch pump with extended wear.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MiniMed Reports Strong Q4 and FY 2026 Results
- International Market Growth: MiniMed achieved net sales of $3.102 billion for FY 2026, reflecting a 14.2% year-over-year increase, with significant growth in international markets, which underscores the company's strong performance and solidifies its leadership in diabetes technology.
- Product Innovation Drive: The global adoption of the MiniMed 780G system continues to rise, with CEO Que Dallara stating that the launches of MiniMed Flex™ and MiniMed Go™ will support long-term growth acceleration and value creation, highlighting the company's ongoing commitment to product innovation.
- Improved Financial Performance: Although MiniMed reported a net loss of $183 million in Q4 2026, its gross margin improved to 57.3%, indicating enhancements in cost control and operational efficiency, which suggests potential for future profitability.
- Optimistic Outlook: MiniMed anticipates continued organic revenue growth in FY 2027, particularly in international markets, which is expected to further drive overall performance, reflecting management's confidence in future business development.
See More
ABIVAX and Others See Significant Stock Gains
- ABIVAX Clinical Trial Success: ABIVAX reported positive results from its Phase 3 ABTECT trial for Obefazimod in ulcerative colitis, achieving primary endpoint of clinical remission at Week 44 with both 25mg and 50mg doses, planning to submit a New Drug Application to the FDA in late Q4 2026, leading to a 24.34% stock increase to $90.15.
- Cingulate Faces FDA Challenge: Cingulate's stock rose 21.09% to $4.88 despite the FDA's rejection of its ADHD drug CTx-1301 application; however, with nearly $30 million in cash reserves, the company aims to resolve CMC issues and proceed with resubmission while continuing pre-commercial activities.
- Alpha Tau Partners with Tolmar: Alpha Tau entered a strategic collaboration with Tolmar to develop and commercialize Alpha DaRT for prostate cancer in the U.S., with Tolmar investing $15 million upfront and $20 million equity stake, while Alpha Tau retains manufacturing rights, resulting in an 18.48% stock increase to $10.58.
- MiniMed Strong Financial Results: MiniMed reported worldwide net sales of $3.102 billion for FY 2026, a 14.2% increase, and expects around 10% organic revenue growth for FY 2027, reflecting strong international market performance and new product launches, with stock rising 15.94% to $14.26.
See More
Minimed Group Reports Strong Q4 Earnings with Robust International Growth
- Significant Revenue Growth: Minimed Group Inc achieved over $3 billion in revenue for fiscal 2026, reflecting an 8% increase, with international revenue growing by 12.2%, indicating strong performance in global markets that is expected to enhance future market share.
- Substantial EBITDA Increase: The company reported an adjusted standalone EBITDA of $154 million in Q4, representing 18.4% of revenue and a 32% year-over-year growth, demonstrating significant operational efficiency improvements that bolster investor confidence.
- New Products Driving Future Growth: The launch of new products such as MiniMed Flex, MiniMed Go, and the Instinct sensor is anticipated to drive future sales growth, particularly in international markets, further solidifying the company's market leadership.
- Optimistic FY27 Outlook: The company projects approximately 10% organic growth for fiscal 2027, especially in the U.S. market, where sales and market penetration are expected to increase progressively with the introduction of new products, reflecting management's confidence in future performance.
See More
MiniMed Group Reports Q4 Earnings Highlights
- Earnings Performance: MiniMed Group reported a Q4 GAAP EPS of -$0.68, missing expectations by $0.38, indicating pressure on profitability that may affect investor confidence.
- Revenue Growth: The company achieved Q4 revenue of $837 million, a 15.6% year-over-year increase, beating expectations by $10.48 million, demonstrating strong sales performance in the market despite the earnings miss.
- Annual Sales Record: MiniMed surpassed $3 billion in net sales for the first time, growing 14% overall and 8% organically, reflecting ongoing expansion in the diabetes management sector and robust market demand.
- Future Outlook: For fiscal year 2027, the company expects approximately 10% organic revenue growth and an adjusted EBITDA margin of around 16%, indicating a positive outlook for future growth despite short-term profitability challenges.
See More
MiniMed Expands Agreement with Abbott for Dual Sensors
- Agreement Expansion: MiniMed's new agreement with Abbott aims to commercialize dual glucose-ketone sensors that will exclusively integrate with MiniMed's smart dosing systems, thereby enhancing choice and simplifying diabetes management, which is expected to significantly improve user experience.
- Real-Time Monitoring Benefits: The new sensors are designed to enable real-time detection of ketone levels to help prevent diabetic ketoacidosis (DKA), a life-threatening complication responsible for hundreds of thousands of hospitalizations annually, indicating that the introduction of this technology will greatly reduce health risks for patients.
- Technology Integration: The dual sensors will seamlessly integrate with MiniMed's smart dosing systems to provide continuous glucose and ketone data, enhancing the safety of automated insulin delivery decisions by ensuring timely alerts when ketone levels begin to rise, thus further improving patient safety.
- Market Outlook: Although Abbott's dual sensors are not yet cleared for sale in the U.S., the recent CE mark approval signifies a major advancement in product development, with further updates on regulatory and commercialization expected in the coming months, showcasing strong market potential.
See More
MiniMed Showcases New Technology at American Diabetes Association Conference
- Technology Showcase: MiniMed will present its latest MiniMed Go™ and MiniMed Flex™ systems at the American Diabetes Association Scientific Sessions from June 5-8, aiming to alleviate the daily burden on diabetes patients through advanced automation and more compact designs, thereby enhancing patients' quality of life.
- Clinical Data Release: The company will share emerging clinical data demonstrating the real-world impact of its connected solutions, particularly highlighting the effectiveness of its recently refreshed sensor portfolio in improving patient health outcomes.
- Interactive Experience: Attendees will have hands-on opportunities to explore the real-time SmartGuard™ automation features of the MiniMed Flex™ system and the memory, reminder, and recommendation capabilities of the MiniMed Go™ smart insulin pen, further enhancing user experience.
- Industry Leadership: As a global leader in insulin delivery, MiniMed continues to advance diabetes treatment technologies in 80 countries, committed to helping patients manage diabetes more easily through an integrated ecosystem and high-quality service, showcasing its innovation and influence in the industry.
See More
MiniMed Reports Strong Q4 and FY 2026 Results
- International Market Growth: MiniMed achieved net sales of $3.102 billion for FY 2026, reflecting a 14.2% year-over-year increase, with significant growth in international markets, which underscores the company's strong performance and solidifies its leadership in diabetes technology.
- Product Innovation Drive: The global adoption of the MiniMed 780G system continues to rise, with CEO Que Dallara stating that the launches of MiniMed Flex™ and MiniMed Go™ will support long-term growth acceleration and value creation, highlighting the company's ongoing commitment to product innovation.
- Improved Financial Performance: Although MiniMed reported a net loss of $183 million in Q4 2026, its gross margin improved to 57.3%, indicating enhancements in cost control and operational efficiency, which suggests potential for future profitability.
- Optimistic Outlook: MiniMed anticipates continued organic revenue growth in FY 2027, particularly in international markets, which is expected to further drive overall performance, reflecting management's confidence in future business development.
See More
ABIVAX and Others See Significant Stock Gains
- ABIVAX Clinical Trial Success: ABIVAX reported positive results from its Phase 3 ABTECT trial for Obefazimod in ulcerative colitis, achieving primary endpoint of clinical remission at Week 44 with both 25mg and 50mg doses, planning to submit a New Drug Application to the FDA in late Q4 2026, leading to a 24.34% stock increase to $90.15.
- Cingulate Faces FDA Challenge: Cingulate's stock rose 21.09% to $4.88 despite the FDA's rejection of its ADHD drug CTx-1301 application; however, with nearly $30 million in cash reserves, the company aims to resolve CMC issues and proceed with resubmission while continuing pre-commercial activities.
- Alpha Tau Partners with Tolmar: Alpha Tau entered a strategic collaboration with Tolmar to develop and commercialize Alpha DaRT for prostate cancer in the U.S., with Tolmar investing $15 million upfront and $20 million equity stake, while Alpha Tau retains manufacturing rights, resulting in an 18.48% stock increase to $10.58.
- MiniMed Strong Financial Results: MiniMed reported worldwide net sales of $3.102 billion for FY 2026, a 14.2% increase, and expects around 10% organic revenue growth for FY 2027, reflecting strong international market performance and new product launches, with stock rising 15.94% to $14.26.
See More
Minimed Group Reports Strong Q4 Earnings with Robust International Growth
- Significant Revenue Growth: Minimed Group Inc achieved over $3 billion in revenue for fiscal 2026, reflecting an 8% increase, with international revenue growing by 12.2%, indicating strong performance in global markets that is expected to enhance future market share.
- Substantial EBITDA Increase: The company reported an adjusted standalone EBITDA of $154 million in Q4, representing 18.4% of revenue and a 32% year-over-year growth, demonstrating significant operational efficiency improvements that bolster investor confidence.
- New Products Driving Future Growth: The launch of new products such as MiniMed Flex, MiniMed Go, and the Instinct sensor is anticipated to drive future sales growth, particularly in international markets, further solidifying the company's market leadership.
- Optimistic FY27 Outlook: The company projects approximately 10% organic growth for fiscal 2027, especially in the U.S. market, where sales and market penetration are expected to increase progressively with the introduction of new products, reflecting management's confidence in future performance.
See More
MiniMed Group Reports Q4 Earnings Highlights
- Earnings Performance: MiniMed Group reported a Q4 GAAP EPS of -$0.68, missing expectations by $0.38, indicating pressure on profitability that may affect investor confidence.
- Revenue Growth: The company achieved Q4 revenue of $837 million, a 15.6% year-over-year increase, beating expectations by $10.48 million, demonstrating strong sales performance in the market despite the earnings miss.
- Annual Sales Record: MiniMed surpassed $3 billion in net sales for the first time, growing 14% overall and 8% organically, reflecting ongoing expansion in the diabetes management sector and robust market demand.
- Future Outlook: For fiscal year 2027, the company expects approximately 10% organic revenue growth and an adjusted EBITDA margin of around 16%, indicating a positive outlook for future growth despite short-term profitability challenges.
See More
MiniMed Expands Agreement with Abbott for Dual Sensors
- Agreement Expansion: MiniMed's new agreement with Abbott aims to commercialize dual glucose-ketone sensors that will exclusively integrate with MiniMed's smart dosing systems, thereby enhancing choice and simplifying diabetes management, which is expected to significantly improve user experience.
- Real-Time Monitoring Benefits: The new sensors are designed to enable real-time detection of ketone levels to help prevent diabetic ketoacidosis (DKA), a life-threatening complication responsible for hundreds of thousands of hospitalizations annually, indicating that the introduction of this technology will greatly reduce health risks for patients.
- Technology Integration: The dual sensors will seamlessly integrate with MiniMed's smart dosing systems to provide continuous glucose and ketone data, enhancing the safety of automated insulin delivery decisions by ensuring timely alerts when ketone levels begin to rise, thus further improving patient safety.
- Market Outlook: Although Abbott's dual sensors are not yet cleared for sale in the U.S., the recent CE mark approval signifies a major advancement in product development, with further updates on regulatory and commercialization expected in the coming months, showcasing strong market potential.
See More
MiniMed Showcases New Technology at American Diabetes Association Conference
- Technology Showcase: MiniMed will present its latest MiniMed Go™ and MiniMed Flex™ systems at the American Diabetes Association Scientific Sessions from June 5-8, aiming to alleviate the daily burden on diabetes patients through advanced automation and more compact designs, thereby enhancing patients' quality of life.
- Clinical Data Release: The company will share emerging clinical data demonstrating the real-world impact of its connected solutions, particularly highlighting the effectiveness of its recently refreshed sensor portfolio in improving patient health outcomes.
- Interactive Experience: Attendees will have hands-on opportunities to explore the real-time SmartGuard™ automation features of the MiniMed Flex™ system and the memory, reminder, and recommendation capabilities of the MiniMed Go™ smart insulin pen, further enhancing user experience.
- Industry Leadership: As a global leader in insulin delivery, MiniMed continues to advance diabetes treatment technologies in 80 countries, committed to helping patients manage diabetes more easily through an integrated ecosystem and high-quality service, showcasing its innovation and influence in the industry.
See More
